Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1997 1
1999 1
2002 1
2003 3
2004 1
2005 1
2006 3
2008 1
2009 5
2010 2
2013 2
2014 6
2015 6
2016 10
2017 10
2018 9
2019 12
2020 19
2021 15
2022 17
2023 15
2024 12
2025 23

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

156 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for busico
Search for Busi O instead (2 results)
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
Cremolini C, Rossini D, Dell'Aquila E, Lonardi S, Conca E, Del Re M, Busico A, Pietrantonio F, Danesi R, Aprile G, Tamburini E, Barone C, Masi G, Pantano F, Pucci F, Corsi DC, Pella N, Bergamo F, Rofi E, Barbara C, Falcone A, Santini D. Cremolini C, et al. JAMA Oncol. 2019 Mar 1;5(3):343-350. doi: 10.1001/jamaoncol.2018.5080. JAMA Oncol. 2019. PMID: 30476968 Free PMC article. Clinical Trial.
Can we define breast cancer HER2 status by liquid biopsy?
Di Cosimo S, De Marco C, Silvestri M, Busico A, Vingiani A, Pruneri G, Cappelletti V. Di Cosimo S, et al. Int Rev Cell Mol Biol. 2023;381:23-56. doi: 10.1016/bs.ircmb.2023.07.003. Epub 2023 Sep 4. Int Rev Cell Mol Biol. 2023. PMID: 37739483 Review.
Is tumour sequencing effective for the identification of germline BRCA1/2 pathogenic variant carriers?
Azzollini J, Capone I, Duca M, Vingiani A, Piccolo A, Agnelli L, Tamborini E, Perrone F, Peissel B, Lorenzini D, Damian S, Vernieri C, Bianchi GV, Mantiero M, Ducceschi M, Polignano M, Niger M, Nichetti F, Proto C, Brambilla M, Colombo E, Stellato M, Conca E, Busico A, Manoukian S. Azzollini J, et al. Tumori. 2024 Dec 9:3008916241280127. doi: 10.1177/03008916241280127. Online ahead of print. Tumori. 2024. PMID: 39311051
End-group-confined chain walking within a group 4 living polyolefin and well-defined cationic zirconium alkyl complexes for modeling this behavior.
Harney MB, Keaton RJ, Sita LR. Harney MB, et al. J Am Chem Soc. 2004 Apr 14;126(14):4536-7. doi: 10.1021/ja0496975. J Am Chem Soc. 2004. PMID: 15070369
For 2' ', the observation that after scrambling each deuterium label is located on a 13C-labeled carbon atom is consistent with the Busico mechanism for chain-end epimerization rather than the Resconi mechanism. Decomposition of 3 yielded olefinic products also consistent …
For 2' ', the observation that after scrambling each deuterium label is located on a 13C-labeled carbon atom is consistent with the Busic …
Epidemiology, ventilation management and outcomes of COVID-19 ARDS patients versus patients with ARDS due to pneumonia in the Pre-COVID era.
van der Ven FLIM, Blok SG, Azevedo LC, Bellani G, Botta M, Estenssoro E, Fan E, Ferreira JC, Laffey JG, Martin-Loeches I, Motos A, Pham T, Peñuelas O, Pesenti A, Pisani L, Neto AS, Schultz MJ, Torres A, Tsonas AM, Paulus F, van Meenen DMP; and for the ERICC–; LUNG SAFE–; PRoVENT–COVID–; EPICCoV–; CIBERESUCICOVID–; SATI–COVID–19–investigators. van der Ven FLIM, et al. Respir Res. 2024 Aug 17;25(1):312. doi: 10.1186/s12931-024-02910-2. Respir Res. 2024. PMID: 39153979 Free PMC article.
Real-World Outcomes of Molecular Tumor Board Treatment Recommendations.
Nichetti F, Brambilla M, Duca M, Piccolo A, Miliziano D, Cavalli C, Marra F, Ambrosini P, Zanella C, Vernieri C, Lorenzini D, Colombo E, Damian S, Baili P, Proto C, Busico A, Conca E, Capone I, Manoukian S, Tamborini E, Perrone F, Niger M, Vingiani A, Agnelli L, de Braud F, Pruneri G. Nichetti F, et al. JCO Precis Oncol. 2025 Jun;9:e2400387. doi: 10.1200/PO-24-00387. Epub 2025 Jun 11. JCO Precis Oncol. 2025. PMID: 40499091 Free PMC article.
Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trial.
Nasca V, Prinzi N, Coppa J, Prisciandaro M, Oldani S, Ghelardi F, Conca E, Capone I, Busico A, Perrone F, Tamborini E, Sabella G, Greco G, Greco FG, Tafuto S, Procopio G, Morano F, Niger M, Maccauro M, Milione M, de Braud F, Pietrantonio F, Pusceddu S. Nasca V, et al. Eur J Cancer. 2024 Sep;209:114276. doi: 10.1016/j.ejca.2024.114276. Epub 2024 Aug 9. Eur J Cancer. 2024. PMID: 39128186 Clinical Trial.
Follow-up program after intensive care unit discharge.
Busico M, das Neves A, Carini F, Pedace M, Villalba D, Foster C, García Urrutia J, Garbarini M, Jereb S, Sacha V, Estenssoro E. Busico M, et al. Med Intensiva (Engl Ed). 2019 May;43(4):243-254. doi: 10.1016/j.medin.2018.12.005. Epub 2019 Mar 2. Med Intensiva (Engl Ed). 2019. PMID: 30833016 English, Spanish.
Genomic instability and CCNE1 amplification as emerging biomarkers for stratifying high-grade serous ovarian cancer.
Conca E, Lorenzini D, Minna E, Agnelli L, Duca M, Gentili M, Bodini B, Polignano M, Mantiero M, Damian S, Devecchi A, Dagrada G, Carminati R, Ardore A, Barbetta F, Da Chuna NB, Guerrizio A, Busico A, Capone I, Piccolo A, Tamborini E, Perrone F, Milione M, Paolini B, Vingiani A, Raspagliesi F, De Braud F, Pruneri G. Conca E, et al. Front Oncol. 2025 Aug 6;15:1633410. doi: 10.3389/fonc.2025.1633410. eCollection 2025. Front Oncol. 2025. PMID: 40842600 Free PMC article.
156 results